Essential thrombocytosis: Difference between revisions
(Created page with "==Background== *Rare, chronic myeloproliferative neoplasm *Abnormal proliferation is seen in megakaryocytic line only *Typically in elderly *Generally asymptomatic ==Clinical...") |
No edit summary |
||
| Line 30: | Line 30: | ||
|- | |- | ||
| Thrombocytosis ≥ 450 x 10<sup>9</sup>L | | Thrombocytosis ≥ 450 x 10<sup>9</sup>L | ||
|- | |||
| Megakaryocyte proliferation with little to no granulocyte or erythroid proliferation | | Megakaryocyte proliferation with little to no granulocyte or erythroid proliferation | ||
|- | |- | ||
| Not meeting criteria for CML, PV, PMF, MDS or other myeloid neoplasm | | Not meeting criteria for CML, PV, PMF, MDS or other myeloid neoplasm | ||
|- | |- | ||
| | | No evidence of reactive thrombocytosis or presence of JAK2V617F or other clonal marker | ||
|} | |} | ||
==Management== | ==Management== | ||
Revision as of 23:33, 15 March 2017
Background
- Rare, chronic myeloproliferative neoplasm
- Abnormal proliferation is seen in megakaryocytic line only
- Typically in elderly
- Generally asymptomatic
Clinical Features
- leukocytosis
- anemia
- splenomegaly
Differential Diagnosis
Evaluation
Workup
- CBC
- Chem 7
- ESR
- Bone marrow biopsy sometimes needed
Evaluation[1]
- Criteria: All category A
| Category A |
|---|
| Thrombocytosis ≥ 450 x 109L |
| Megakaryocyte proliferation with little to no granulocyte or erythroid proliferation |
| Not meeting criteria for CML, PV, PMF, MDS or other myeloid neoplasm |
| No evidence of reactive thrombocytosis or presence of JAK2V617F or other clonal marker |
Management
- ASA 81mg
- Myelosuppressive agents (hydroxyurea, interferon alpha)
Also See
References
- ↑ Tefferi, A, et al. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer. 2009; 115(17):3842-7,